Login to Your Account


Vertex surges on robust CF data with VX-809/Kalydeco; expects 4Q NDA

By Karen Pihl-Carey
Staff Writer

Tuesday, June 24, 2014
Consistent phase III cystic fibrosis (CF) data for a combination regimen of Vertex Pharmaceuticals Inc.'s VX-809 (lumacaftor) and Kalydeco (ivacaftor) offered marked improvements in lung function, and hit multiple secondary endpoints, driving the Boston-based company's stock up by 40 percent Tuesday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription